CAR-T Cell Immunotherapy for HCC Targeting GPC3

Exclusion Criteria

• •1. Pregnant and lactating women.
• •2. Lymphocyte separation or peripheral venous access cannot be performed in patients .
• •3. Patients in the active stage of infection or with coagulation disorders.
• •4. Patients with a previous history of hepatic coma.
• •5. Patients with severe gastrointestinal ulcers or gastrointestinal bleeding.
• •6. Patients with organ transplantation or waiting for organ transplantation.
• •7. Patients with anticoagulant therapy.
• •8. Patients with antiplatelet therapy.
• •9. Serum sodium(Na)\<125 mmol/L.
• •10. Serum potassium(K)\<3.5 mmol/L(except patients up to the standards after the use of supplements).
• •11. Patients with organ failure：
• •1. cardiac function：level three or above according to New York Heart Association (NYHA) criteria.
• •2. liver function:class C or above according to Child-puge grading standard.
• •3. renal function:Chronic kidney disease(CKD) phase 4 or more; renal insufficiency phase Ⅲ or more.
• •4. pulmonary function：severe respiratory failure symptoms, involving other organs.
• •5. Brain function:central nervous system abnormalities or disturbance of consciousness.
• •12. Patients with non controlled infectious diseases,for example,HIV positive, syphilis, hepatitis A, hepatitis B, hepatitis C, hepatitis E virus (HEV) positive etc.
• •13. Patients used corticosteroids or other immunosuppressive agents in the past 4 weeks.
• •14. Patients with autoimmune disease.
• •15. Patients with previous history of gene therapy.
• •16. The actual transfection rate of T cells was lower than 30% or the proliferation was less than 5 times after costimulation.
• •17. Patients participated in other drug trials in the past 4 weeks.
• •18. Patients received radiation treatment in the past 4 weeks.
• •19. Patients do not meet the criteria above.